Friend MTS, Leading Global Provider of Content Protection Services, Announces Appointment of Derek Chang to Chief Executive Officer
2.6.2021 14:00:00 EEST | Business Wire | Press release
Friend MTS is pleased to announce the appointment of Derek Chang to Chief Executive Officer (CEO). A seasoned industry executive with a career spanning three decades, Chang previously served as CEO of NBA China, and has held leadership positions with several recognized sports, media and entertainment providers. He will be based in London.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005316/en/
Derek Chang, Chief Executive Officer, Friend MTS (Photo: Business Wire)
“It is my privilege to join Friend MTS as we ramp up our innovation of the technology essential to protect the needs of a complex global media industry,” said Chang. “We are at the forefront of rapid changes in consumer behavior, new business models and technology, and will ensure that creators, owners and distributors worldwide will have the formidable tools necessary to protect their valuable content.”
The announcement was made today by Jonathan Friend, Founder, Friend MTS, who previously served as CEO. A visionary in the field of content protection technologies, Friend will serve as Chief Product Officer (CPO) and continue to drive growth through the creation of the company’s advanced proprietary solutions.
“As we continue to innovate with groundbreaking solutions that our valued customers and partners have come to expect, now is the time to transition to our next leader and we are thrilled to welcome Derek to the helm of Friend MTS,” said Friend. “With deep expertise in the global sports and entertainment space, Derek brings invaluable insight to leveraging technology to create an impactful footprint for an ever-evolving media and content ecosystem.”
Prior to leading NBA China’s business, Chang was Head of International Lifestyle Channels for Scripps Networks Interactive, and had served as Executive Vice President, Content, DIRECTV. He also held senior roles for Charter Communications, the YES Network and TCI Communications. Chang currently serves on the board of directors for Liberty Media Corp. and Isos Acquisition Corp., and formerly served on the board of Starz.
Chang was named one of the “50 Most Influential People in Sports Business” by Sports Business Journal, as well as Cablefax Magazine's “Top 100 Executives in Cable.” He holds an MBA from Stanford University and a bachelor's degree in history from Yale University. He is a member of the Committee of 100 and serves on the advisory board of Row New York.
For press use, Friend MTS photo assets can be downloaded here. For more information, please visit www.friendmts.com or follow on LinkedIn and Twitter.
About Friend MTS:
Friend MTS is a leading global provider of innovative content protection technology solutions developed to advance a complex and ever-evolving media industry in collaboration with content owners, broadcasters and operators. With a comprehensive suite of advanced proprietary services ranging from content monitoring, fingerprinting and watermarking to enforcement and IP blocking, Friend MTS provides an end-to-end approach to disrupt real-world piracy and safeguard a worldwide entertainment and media market into the future. Playing an important role in social responsibility, Friend MTS has gifted organizations like the U.S. Department of Homeland Security and the International Center for Missing and Exploited Children (ICMEC) with its award-winning technology to help combat online child abuse. Founded in 2000, Friend MTS is privately held and headquartered in Birmingham, U.K. and Philadelphia, Pennsylvania, with operations throughout Europe, Asia, the Middle East, Africa, Latin America and North America.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005316/en/
Contact information
Friend MTS Media Contact:
Nora Ellish
+1 (917) 744-9200
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
